Galux and Boehringer Ingelheim Ink Agreement for AI-Driven Protein Design

South Korean biotech company Galux announced on December 18, 2025, that it has signed a joint research agreement with global pharmaceutical leader Boehringer Ingelheim. The partnership focuses on utilizing the GaluxDesign platform to create functional proteins "from scratch" (de novo). Unlike traditional methods, Galux's AI platform allows for designing molecules with predefined therapeutic properties, which could significantly accelerate drug discovery for complex biological targets that are difficult to address with standard approaches.

The collaboration aims to validate AI's capabilities not just in predicting the structures of existing proteins, but in the purposeful creation of new molecular solutions for medicine. For Galux, this is its first major international agreement of this magnitude, underscoring the growing role of Korean AI technologies in global pharmaceuticals. The parties plan to evaluate the platform's effectiveness across several pilot projects, after which a decision will be made on expanding the partnership into a long-term commercial contract.

Source: BioSpectrum Asia